Linde, LouiseGeorgiadis, StylianosØrnbjerg, Lykke M.Rasmussen, Simon H.Michelsen, BrigitteAskling, JohanDi Giuseppe, DanielaWallman, Johan K.Závada, JakubPavelka, KarelBernardes, MiguelMatos, Carolina O.Glintborg, BenteLoft, Anne GitteNordström, DanKuusalo, LauraMöller, BurkhardNissen, Michael J.Codreanu, CatalinMogosan, CorinaGudbjornsson, BjornLove, Thorvardur JonAkleylek, CansuIannone, FlorenzoKvien, Tore K.Rotar, ZigaCastrejon, IsabelMacfarlane, Gary J.Hetland, Merete L.Østergaard, Mikkel2025-07-222025-07-222024-11Linde, L, Georgiadis, S, Ørnbjerg, L M, Rasmussen, S H, Michelsen, B, Askling, J, Di Giuseppe, D, Wallman, J K, Závada, J, Pavelka, K, Bernardes, M, Matos, C O, Glintborg, B, Loft, A G, Nordström, D, Kuusalo, L, Möller, B, Nissen, M J, Codreanu, C, Mogosan, C, Gudbjornsson, B, Love, T J, Akleylek, C, Iannone, F, Kvien, T K, Rotar, Z, Castrejon, I, Macfarlane, G J, Hetland, M L & Østergaard, M 2024, 'Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries', Arthritis Care and Research, vol. 76, no. 11, pp. 1558-1565. https://doi.org/10.1002/acr.253962151-464XORCID: /0000-0003-2322-3314/work/188766422https://hdl.handle.net/2164/25732ACKNOWLEDGMENTS We acknowledge Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration.8877259engR Medicine (General)RheumatologyR1Journal article10.1002/acr.25396http://www.scopus.com/inward/record.url?scp=85201548710&partnerID=8YFLogxK7611